Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
CASE REPORT
Ahead of Print

Recurrence of renal cell carcinoma after three decades in an octogenarian: Small molecules adding life to years


1 Department of Medical Oncology and Hematology, Amrita Institute of Medical Sciences, Ponekkara, Kochi, Kerala, India
2 Department of Pathology, Amrita Institute of Medical Sciences, Ponekkara, Kochi, Kerala, India

Correspondence Address:
Arun Philip,
Department of Medical Oncology and Hematology, Amrita Institute of Medical Sciences, Ponekkara, Kochi - 682 041, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_989_19

Renal cell carcinoma (RCC) is the most common primary renal neoplasm. About a half of our patients relapse after primary treatment. We present here a case of RCC with solitary metastasis to the pleura which occurred 32 years after nephrectomy. Our patient is an 86-year-old male who presented to us with a cough of 2 months and a history of having undergone a right nephrectomy 32 years back. Imaging of the chest showed left pleural effusion with a left pleural nodule. Computed tomography-guided fine-needle aspiration cytology from the pleural nodule was suggestive of malignancy with a clear cell morphology, suggestive of clear cell RCC. The patient was started on sunitinib 25 mg once daily. After the 1st month, the patient's performance status improved markedly, with no cough and improved appetite. He had developed Grade II hand–foot syndrome, which was managed conservatively, and the dose was deescalated to 25 mg once daily – 5 days on and 2 days off. An X-ray of the chest taken 6 weeks after the start of therapy showed complete resolution of the pleural fluid and regression of the pleural nodule. The patient is alive and well 5 years into therapy. The case highlights the unusual propensity for very late metastasis in RCC. Metastasis after 30 years is extremely rare. Another highlight of the case is the good tolerability of the dose-modified schedule of sunitinib. Wise patient selection and dose modification can certainly add “life to the years” in our very elderly patients.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Philip A
    -  Jojo A
    -  Keechilat P
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed37    
    PDF Downloaded2    

Recommend this journal